852678
6-巯基嘌呤 一水合物
98%
别名:
6-嘌呤硫醇, 6-硫代嘌呤
登录 查看组织和合同定价。
选择尺寸
关于此项目
经验公式（希尔记法）:
C5H4N4S · H2O
化学文摘社编号:
分子量:
170.19
UNSPSC Code:
12352005
NACRES:
NA.22
PubChem Substance ID:
EC Number:
200-037-4
Beilstein/REAXYS Number:
4012091
MDL number:
Assay:
98%
Form:
powder
产品名称
6-巯基嘌呤 一水合物, 98%
InChI key
WFFQYWAAEWLHJC-UHFFFAOYSA-N
InChI
1S/C5H4N4S.H2O/c10-5-3-4(7-1-6-3)8-2-9-5;/h1-2H,(H2,6,7,8,9,10);1H2
SMILES string
O.Sc1ncnc2[nH]cnc12
assay
98%
form
powder
mp
>300 °C (lit.)
Quality Level
Gene Information
human ... PPAT(5471)
正在寻找类似产品? 访问 产品对比指南
Application
6-巯基嘌呤是一种广泛使用的抗白血病药物，可通过将硫嘌呤甲基转移酶代谢物插入DNA和RNA而抑制从头的嘌呤合成。
General description
6-巯基嘌呤一水合物是一种抗代谢物和抗肿瘤药物。它与4-羟基苯甲酸以及2,4-二羟基苯甲酸的共结晶或与哌嗪的盐形成可提高其水溶性。
signalword
Danger
hcodes
Hazard Classifications
Acute Tox. 3 Oral - Muta. 2 - Repr. 2
存储类别
6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects
wgk
WGK 3
ppe
dust mask type N95 (US), Eyeshields, Gloves
The crystal and molecular structure of 6-mercaptopurine monohydrate.
Sletten E, et al.
Acta Crystallographica Section B, Structural Science, Crystal Engineering and Materials, 25(7), 1330-1338 (1969)
Comparative structural and spectrum analyses of 6-mercaptopurine monohydrate and 6-mercaptopurine hydrochloride
Perez-Ruiz E, et al.
Canadian Journal of Analytical Sciences and Spectroscopy, 43(3), 59-67 (1998)
Clinical pharmacogenetics implementation consortium guidelines for thiopurine methyltransferase genotype and thiopurine dosing: 2013 update.
M V Relling et al.
Clinical pharmacology and therapeutics, 93(4), 324-325 (2013-02-21)
William J Sandborn et al.
Gastroenterology, 146(1), 85-95 (2013-06-06)
Little is known about the efficacy of golimumab, a fully human monoclonal antibody to tumor necrosis factor (TNF) -α, for treatment of ulcerative colitis (UC). We evaluated subcutaneous golimumab induction therapy in TNF-α antagonist-naïve patients with moderate-to-severe UC despite conventional
Helmut Gadner et al.
Blood, 121(25), 5006-5014 (2013-04-17)
Langerhans cell histiocytosis (LCH)-III tested risk-adjusted, intensified, longer treatment of multisystem LCH (MS-LCH), for which optimal therapy has been elusive. Stratified by risk organ involvement (high [RO+] or low [RO-] risk groups), > 400 patients were randomized. RO+ patients received
我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系客户支持